---
layout: post
title: New Drug Approvals 2013 - Pt. XVIII - Obinutuzumab (GazyvaTM)
date: '2013-11-15T07:01:00.003Z'
author: Bissan Al-Lazikani
tags:
- Cancer
- 2013 New Drugs
- Black Box Warning Drugs
modified_time: '2013-11-15T09:29:05.138Z'
thumbnail: http://1.bp.blogspot.com/-jNQZ-cdVmdg/UoWrDpc99lI/AAAAAAAAAOk/8MbBJmNk45w/s72-c/Gazyva.jpg
blogger_id: tag:blogger.com,1999:blog-2546008714740235720.post-6860879307354818736
blogger_orig_url: http://chembl.blogspot.com/2013/11/new-drug-approvals-2013-pt-xviii.html
---

<center>
<div class="separator" style="clear: both; text-align: center;">
<a href="http://1.bp.blogspot.com/-jNQZ-cdVmdg/UoWrDpc99lI/AAAAAAAAAOk/8MbBJmNk45w/s1600/Gazyva.jpg" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" src="http://1.bp.blogspot.com/-jNQZ-cdVmdg/UoWrDpc99lI/AAAAAAAAAOk/8MbBJmNk45w/s200/Gazyva.jpg" /></a></div>
<div class="separator" style="clear: both; text-align: center;">
<br /></div>
<img src="https://www.ebi.ac.uk/chembltools/autoiconlarge2/6,0,0,2,0,0,1,0,1,1" width="400" /><br />
<b><br /></b></center>
<center>
<b>ATC Code:&nbsp;</b><span style="background-color: #f0f0f0; font-family: Verdana, Arial, Helvetica, sans-serif; font-size: 12px; line-height: 18px;">L01XC15</span>
</center>
<center>
<b>Wikipedia: </b><a href="http://en.wikipedia.org/wiki/Obinutuzumab">Obinutuzumab</a></center>
<br />
On November 1, 2013 the FDA approved obinutuzumab (Gazyva<sup>TM</sup>) for use in combination with <a href="http://en.wikipedia.org/wiki/Chlorambucil">chlorambucil</a>&nbsp;(a nitrogen mustard alkylating agent) for the treatment of patients with previously untreated chronic lymphocytic leukemia (CLL). CLL is the most common type of Leukaemia accounting for 35% of all reported Leukaemias (See <a href="http://www.cancerresearchuk.org/cancer-help/type/cll/treatment/statistics-and-outlook-for-chronic-lymphocytic-leukaemia">CRUK CLL</a> page). In a randomized three-arm clinical study, the combination of obinutuzumab (in combination with chlorambucil) improved the progression-free survival (PFS) of patients to 23.0 months compared to 11.1 months for chlorambucil alone.<br />
<br />
<div class="separator" style="clear: both; text-align: center;">
<a href="http://3.bp.blogspot.com/-b7F3FUPmCLU/UoWvyxIKMkI/AAAAAAAAAOw/IZTrtM6O738/s1600/cd20.png" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" src="http://3.bp.blogspot.com/-b7F3FUPmCLU/UoWvyxIKMkI/AAAAAAAAAOw/IZTrtM6O738/s200/cd20.png" /></a></div>
<br />
Obinutuzumab (<a href="https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1743048">CHEMBL1743048</a>) is a humanized anti-CD20 monoclonal antibody of <i>ca</i>. 150 kDa molecular weight. Its target, the B-lymphicyte antigen CD20, is the product of the gene MS4A1 (Uniprot: P11836; ChEMBL: <a href="https://www.ebi.ac.uk/chembl/target/inspect/CHEMBL2058">CHEMBL2058</a>; <a href="https://cansar.icr.ac.uk/cansar/molecular-targets/P11836/">canSAR target synopsis</a>. The CD20 antigen is expressed on the surface of pre B- and mature B-lymphocytes. Obinutuzumab mediates B-cell lysis through three main routes: <br />
<ul>
<li>Engagement of immune effector cells, resulting in antibody-dependent cellular cytotoxicity and antibody-dependent cellular phagocytosis<br />
</li>
<li>Direct activation of intracellular death signaling pathways <br />
</li>
<li>Activation of the complement cascade. <br />
</li>
</ul>
<pre>&gt;obinutuzumab
QVQLVQSGAEVKKPGSSVKVSCKASGYAFSYSWINWVRQAPGQGLEWMGR&nbsp;</pre>
<pre>IFPGDGDTDYNGKFKGRVTITADKSTSTAYMELSSLRSEDTAVYYCARNV&nbsp;</pre>
<pre>FDGYWLVYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKD&nbsp;</pre>
<pre>YFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTY&nbsp;</pre>
<pre>ICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPK&nbsp;</pre>
<pre>DTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNS&nbsp;</pre>
<pre>TYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQV&nbsp;</pre>
<pre>YTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVL&nbsp;</pre>
<pre>DSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK/</pre>
<pre>DIVMTQTPLSLPVTPGEPASISCRSSKSLLHSNGITYLYWYLQKPGQSPQ&nbsp;</pre>
<pre>LLIYQMSNLVSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCAQNLELP&nbsp;</pre>
<pre>YTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAK&nbsp;</pre>
<pre>VQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACE&nbsp;</pre>
<pre>VTHQGLSSPVTKSFNRGEC</pre>
<div>
<br /></div>
The geometric mean (CV%) volume of distribution of obinutuzumab at steady state is approximately 3.8L. The terminal clearance is 0.09 (46%) L/day and the terminal half-life is ~28.4 days.  <br />
<br />
Obinutuzumab has been issued with a boxed warning because of the following observed events: Reactivation of Hepatitis B Virus (HBV), in some cases resulting in fulminant hepatitis, hepatic failure, and death; and causing Progressive Multifocal Leukoencephalopathy (PML) resulting in death. <br />
<br />
Gazyva<sup>TM</sup> is produced by <a href="http://www.gene.com/media/press-releases/14560/2013-11-07/genentechs-gazyva-helped-people-with-one">Genentech, Inc.</a>
The full Prescribing Information is <a href="http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/125486s000lbl.pdf">here</a>.<br />
<br />